NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have received a consensus recommendation of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $8.50.

NRSN has been the subject of a number of analyst reports. D. Boral Capital restated a “buy” rating and issued a $14.00 price target on shares of NeuroSense Therapeutics in a research report on Wednesday, April 8th. Weiss Ratings restated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research report on Friday, May 8th. Finally, Roth Mkm assumed coverage on NeuroSense Therapeutics in a research report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price target for the company.

Insider Activity at NeuroSense Therapeutics

In other NeuroSense Therapeutics news, CEO Alon Ben-Noon acquired 250,000 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was bought at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the transaction, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at approximately $3,627,386.40. The trade was a 5.84% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Or Eisenberg acquired 250,000 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was acquired at an average price of $0.80 per share, with a total value of $200,000.00. Following the completion of the transaction, the chief financial officer directly owned 1,504,050 shares of the company’s stock, valued at $1,203,240. This trade represents a 19.94% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 27.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in NRSN. Two Sigma Investments LP purchased a new position in NeuroSense Therapeutics in the third quarter worth approximately $26,000. Jane Street Group LLC purchased a new position in NeuroSense Therapeutics in the second quarter worth approximately $54,000. Yorkville Advisors Global LP purchased a new position in NeuroSense Therapeutics in the fourth quarter worth approximately $77,000. Finally, Squarepoint Ops LLC grew its position in NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares during the period. 1.04% of the stock is currently owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Price Performance

Shares of NeuroSense Therapeutics stock opened at $0.71 on Thursday. The business has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $0.86. The stock has a market capitalization of $22.95 million, a P/E ratio of -1.31 and a beta of 1.56. NeuroSense Therapeutics has a 12 month low of $0.63 and a 12 month high of $2.52.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.